The U.S. Food and Drug Administration (FDA) has recognized Eli Lilly and Co (NYSE:LLY) with a significant milestone by awarding orphan drug status to its promising new treatment, olomorasib. This designation is specifically for its potential in treating KRAS G12C-mutant non-small cell lung cancer, a form of cancer that has been challenging to manage. Currently, olomorasib is advancing through phase 3 clinical trials, where it is being evaluated for efficacy in combination with Keytruda and chemotherapy as a first-line therapy for patients with advanced cases.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.